AVID-200 is under clinical development by Bristol-Myers Squibb and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect AVID-200’s likelihood of approval (LoA) and phase transition for Head And Neck Cancer Squamous Cell Carcinoma took place on 22 Nov 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their AVID-200 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

AVID-200 overview

AVID-200 is under development for the treatment of solid tumors including triple negative breast cancer, non-small cell lung cancer (NSCLC), urothelial carcinoma (UC), squamous cell carcinoma of the head and neck (SCCHN), Hhepatocellular carcinoma (HCC), microsatellite-stable colorectal carcinoma (MSS CRC), or pancreatic ductal adenocarcinoma, anemia associated with myelodysplastic syndrome, primary myelofibrosis, post-essential thrombocythemia myelofibrosis and post-polycythemia vera myelofibrosis and systemic sclerosis (scleroderma). It is administered by intravenous route. The drug candidate is an antibody-drug conjugate, computationally designed class of avidity-enhanced receptor-ectodomain-based trap that binds and neutralizes TGF-beta 1 and 3. The drug candidate was also under development for the treatment of idiopathic pulmonary fibrosis.

Bristol-Myers Squibb overview

Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, hospitals, medical professionals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.

Quick View AVID-200 LOA Data

Report Segments
  • Innovator
Drug Name
  • AVID-200
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Hematological Disorders
  • Immunology
  • Oncology
  • Respiratory
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.